Shares of BioNTech surged 6% to $102.55 on September 14, defying a weak market session with Nasdaq futures down nearly 1.5%, after the German biotech reported that its experimental cancer drug nearly doubled survival in a tough-to-treat form of lung cancer. The move reclaims ground lost over the prior week and raises a pointed question: can oncology pipeline wins finally shift BioNTech's identity — and valuation — beyond its COVID vaccine origins? BioNTech's Cancer Drug Nearly Doubles Lung Cancer Survival — But Is One Small Trial Enough to Rewrite the Post-COVID Playbook?
Shares of BioNTech jumped 6% to $102.55 on September 14, bucking a weak session with Nasdaq futures down 1.5%, after updated clinical data showed its experimental cancer drug nearly doubled survival in patients with a hard-to-treat form of lung cancer. The rally poses a critical question: can pipeline wins like this offset the company's rapidly shrinking COVID-19 vaccine business fast enough to matter?
• Patients Lived Nearly Twice as Long, But the Study Was Tiny. Median overall survival was 18.5 months with gotistobart versus 10.0 months with standard chemotherapy (docetaxel), a statistically significant result with a hazard ratio of 0.56. That's a striking improvement in a population where survival expectations are grim. However, the trial enrolled just 87 patients — 45 on the drug, 42 on chemo.
The pivotal second stage of the trial, running at more than 160 sites globally, is still ongoing and will ultimately determine whether regulators approve it. Today's data is encouraging but not conclusive.
• COVID Revenue Is Cratering and the Clock Is Ticking. BioNTech desperately needs oncology wins because its core business is evaporating. The company slashed its 2026 revenue outlook to €1.6–1.9 billion from €2.0–2.3 billion , and Q2 revenue was just €105.6 million, with a net loss of €820.8 million in the quarter and €1.35 billion in the first half.
Roughly 80% of the guidance cut was tied to falling COVID vaccine demand. Gotistobart's success matters because the company is spending heavily on R&D — over €500 million per quarter — while its revenue base shrinks.
• A €16.6 Billion Cash Pile Buys Time, Not Revenue. BioNTech ended Q2 with €16.6 billion in cash and investments , a war chest that funds an enormous pipeline. The company says its lung cancer program alone includes more than 16 clinical trials, with five Phase 3 studies. That's a luxury few biotechs enjoy, but most programs are still in development and have not yet produced commercial revenue.
• The Real Test Is Whether This Drug Becomes a Product. Patients with this type of lung cancer have had no meaningful new option for "more than a decade," making the unmet need real. But gotistobart targets a niche — second-line squamous lung cancer — not a blockbuster-sized market. Management expects seven late-stage oncology readouts and 15 Phase 3 trials ongoing by year-end 2026, aiming to become a "multi-product oncology company" through the 2030s. Today's data is a credibility milestone, but investors are still betting on a transformation story that won't pay off commercially for years.